Compared to standardized biomarkers, RIPK2 was more accurate and valuable in predicting immunotherapy outcome for patients with GBM (Zhao2019_PD1_ Glioblastoma, AUC = 0.83) or HNSC (Uppaluri2020_PD1_HNSC, AUC = 0.88) (Fig. 5C). This evidence concerns the gene RIPK2 and glioblastoma.